Advertisement
DXCM vs NVST
Which Stock Would AI Choose? DexCom (DXCM) vs. Envista (NVST) Stock Comparison
Key Takeaways
- NVST has significantly outperformed DXCM year-to-date (YTD), with gains of approximately 23% compared to DXCM's 7%.
- Recent quarterly earnings for NVST showed 15% revenue growth and a swing to profitability, driving a sharp stock rally, while DXCM beat estimates but experienced share price weakness.
- DXCM boasts a larger market capitalization of about $24 billion versus NVST's $4.4 billion, reflecting greater scale in the continuous glucose monitoring (CGM) market.
- Both stocks operate in medical technology, but DXCM focuses on diabetes management while NVST specializes in dental products, offering distinct growth drivers.
- Analyst price targets suggest upside for both, with DXCM at around $87 and NVST at $29, indicating potential relative value opportunities.
- Tickeron's AI tools highlight momentum favoring NVST in current market conditions.
Introduction
In the competitive medical technology sector, DXCM and NVST represent distinct niches: continuous glucose monitoring for diabetes care versus dental equipment and consumables. This stock comparison evaluates their recent performance, business models, and market positioning amid evolving healthcare demands. Traders seeking momentum plays may eye NVST's surge, while long-term investors might value DXCM's established recurring revenue streams. Understanding these dynamics aids in assessing relative performance and sector rotation opportunities in today's market environment.
DXCM Overview and Recent Performance
DexCom, Inc. develops and commercializes CGM systems, enabling real-time glucose tracking for diabetes patients through wearable sensors and apps. The company's subscription-like model drives recurring revenue, bolstered by innovations like the G7 sensor, which has seen strong uptake in recent market activity.
Shares have traded around $61 in recent weeks, down from a 52-week high near $90, reflecting broader medtech pressures despite solid fundamentals. In the latest quarterly results, DexCom reported 13% revenue growth and non-GAAP EPS (earnings per share) of $0.68, surpassing expectations. However, the stock dipped post-earnings amid valuation concerns and anticipation for Q1 2026 results. Sentiment remains supported by analyst upgrades and a forward price-to-earnings (P/E) ratio of about 29, with YTD gains of 7% signaling stability over high volatility.
NVST Overview and Recent Performance
Envista Holdings Corporation supplies dental products, including implants, orthodontics, and imaging equipment, serving professionals worldwide. Its portfolio emphasizes consumables and digital solutions, capitalizing on steady demand in restorative dentistry.
Trading near $27 recently, NVST shares have rallied from 52-week lows around $15, achieving YTD gains of 23% and one-year returns exceeding 60%. Recent quarterly earnings highlighted 15% revenue growth to $751 million and a profitable turnaround, exceeding forecasts and prompting a 20%+ post-earnings surge. This momentum reflects operational improvements and share repurchases, though a higher trailing P/E of 96 underscores recovery dynamics. Market sentiment has improved with analyst target hikes, positioning NVST for continued strength in recent trading sessions.
Trending AI Robots
Tickeron's Trending AI Robots page showcases the platform's top-performing AI trading bots, selected from over 351 total bots that analyze and trade thousands of tickers across diverse strategies. Only 25 elite bots earn a spot in this curated section, chosen by AI for their suitability to current market conditions, including varying timeframes (e.g., 5-minute to 60-minute), volatility levels (low to high), and approaches like technical or fundamental analysis. These bots deliver real-time signals for copy trading via Signal Agents, risk-managed virtual portfolios, or brokerage executions, with historical performances often featuring high win rates and attractive average returns. Exploring these tools can reveal automated insights tailored to stocks like DXCM and NVST—visit the page to discover bots matching your trading style today.
Head-to-Head Comparison
DexCom and Envista diverge in business models: DXCM's sensor-as-a-service generates predictable revenue (TTM $4.7 billion), contrasting NVST's product sales cycle (TTM $2.7 billion). Growth drivers include DXCM's G7 expansion amid diabetes prevalence versus NVST's double-digit segment gains from dental recovery.
Recent momentum favors NVST's 10%+ monthly advances over DXCM's consolidation, with NVST's YTD edge highlighting relative strength. Risk factors differ—DXCM faces competition in CGM and reimbursement hurdles, while NVST contends with economic sensitivity in elective dentistry and higher beta. Sector exposure ties both to medtech tailwinds like aging populations, but DXCM benefits from chronic care stability versus NVST's cyclicality. Market sentiment leans toward NVST's turnaround narrative, though DXCM's scale offers lower volatility for conservative positioning.
Tickeron AI Verdict
Tickeron's AI currently favors NVST over DXCM, driven by superior trend consistency, YTD outperformance, and post-earnings catalysts signaling sustained momentum. While DXCM maintains stability and innovation upside, NVST's relative positioning in recent market activity suggests higher probability of near-term gains for momentum-oriented strategies.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DXCM is a Buy and NVST is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
DXCM’s FA Score shows that 1 FA rating(s) are green whileNVST’s FA Score has 0 green FA rating(s).
- DXCM’s FA Score: 1 green, 4 red.
- NVST’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
DXCM’s TA Score shows that 6 TA indicator(s) are bullish while NVST’s TA Score has 6 bullish TA indicator(s).
- DXCM’s TA Score: 6 bullish, 4 bearish.
- NVST’s TA Score: 6 bullish, 4 bearish.
Price Growth
DXCM (@Medical/Nursing Services) experienced а +2.00% price change this week, while NVST (@Pharmaceuticals: Other) price change was -2.38% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -0.24%. For the same industry, the average monthly price growth was -0.16%, and the average quarterly price growth was -16.01%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +0.72%. For the same industry, the average monthly price growth was +1.78%, and the average quarterly price growth was -13.43%.
Reported Earning Dates
DXCM is expected to report earnings on Jul 23, 2026.
NVST is expected to report earnings on Aug 05, 2026.
Industries' Descriptions
@Medical/Nursing Services (-0.24% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Pharmaceuticals: Other (+0.72% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
| DXCM | NVST | DXCM / NVST | |
| Capitalization | 28.1B | 3.65B | 771% |
| EBITDA | 1.48B | 388M | 381% |
| Gain YTD | 9.643 | 3.178 | 303% |
| P/E Ratio | 31.23 | 54.63 | 57% |
| Revenue | 4.82B | 2.81B | 172% |
| Total Cash | 2.42B | 1.08B | 223% |
| Total Debt | 1.39B | 1.59B | 87% |
DXCM | NVST | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 40 | 53 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 75 Overvalued | 71 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 27 | 90 | |
PRICE GROWTH RATING 1..100 | 44 | 59 | |
P/E GROWTH RATING 1..100 | 94 | 65 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NVST's Valuation (71) in the null industry is in the same range as DXCM (75) in the Medical Specialties industry. This means that NVST’s stock grew similarly to DXCM’s over the last 12 months.
NVST's Profit vs Risk Rating (100) in the null industry is in the same range as DXCM (100) in the Medical Specialties industry. This means that NVST’s stock grew similarly to DXCM’s over the last 12 months.
DXCM's SMR Rating (27) in the Medical Specialties industry is somewhat better than the same rating for NVST (90) in the null industry. This means that DXCM’s stock grew somewhat faster than NVST’s over the last 12 months.
DXCM's Price Growth Rating (44) in the Medical Specialties industry is in the same range as NVST (59) in the null industry. This means that DXCM’s stock grew similarly to NVST’s over the last 12 months.
NVST's P/E Growth Rating (65) in the null industry is in the same range as DXCM (94) in the Medical Specialties industry. This means that NVST’s stock grew similarly to DXCM’s over the last 12 months.
| DXCM | NVST | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 70% | 2 days ago 72% |
| Stochastic ODDS (%) | 2 days ago 65% | 2 days ago 72% |
| Momentum ODDS (%) | 2 days ago 72% | 2 days ago 71% |
| MACD ODDS (%) | 2 days ago 76% | 2 days ago 60% |
| TrendWeek ODDS (%) | 2 days ago 69% | 2 days ago 70% |
| TrendMonth ODDS (%) | 2 days ago 72% | 2 days ago 69% |
| Advances ODDS (%) | 3 days ago 70% | 29 days ago 62% |
| Declines ODDS (%) | 8 days ago 72% | 2 days ago 71% |
| BollingerBands ODDS (%) | 2 days ago 60% | 2 days ago 67% |
| Aroon ODDS (%) | 2 days ago 67% | 2 days ago 64% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| MGF | 2.84 | N/A | N/A |
| MFS Government Markets Income Trust | |||
| QCJA | 23.36 | -0.02 | -0.09% |
| FT Vest Nasdaq-100 Cnsrv Buffr ETF - Jan | |||
| ZJUN | 27.44 | -0.04 | -0.16% |
| Innovator Equity Dfnd Prot ETF -1 YrJune | |||
| TECB | 72.88 | -0.66 | -0.89% |
| iShares US Tech Breakthrough Mltsctr ETF | |||
| EWC | 58.64 | -0.82 | -1.38% |
| iShares MSCI Canada ETF | |||
DXCM and
Correlation & Price change
A.I.dvisor indicates that over the last year, DXCM has been loosely correlated with ISRG. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if DXCM jumps, then ISRG could also see price increases.
| Ticker / NAME | Correlation To DXCM | 1D Price Change % | ||
|---|---|---|---|---|
| DXCM | 100% | -0.93% | ||
| ISRG - DXCM | 46% Loosely correlated | +1.24% | ||
| ALGN - DXCM | 44% Loosely correlated | -2.99% | ||
| SYK - DXCM | 41% Loosely correlated | +0.58% | ||
| NVST - DXCM | 40% Loosely correlated | -2.35% | ||
| GKOS - DXCM | 39% Loosely correlated | +2.58% | ||
More | ||||
NVST and
Correlation & Price change
A.I.dvisor indicates that over the last year, NVST has been loosely correlated with XRAY. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if NVST jumps, then XRAY could also see price increases.
| Ticker / NAME | Correlation To NVST | 1D Price Change % | ||
|---|---|---|---|---|
| NVST | 100% | -2.35% | ||
| XRAY - NVST | 62% Loosely correlated | -1.88% | ||
| BIO - NVST | 57% Loosely correlated | -0.42% | ||
| ALGN - NVST | 56% Loosely correlated | -2.99% | ||
| A - NVST | 55% Loosely correlated | +1.74% | ||
| MTD - NVST | 52% Loosely correlated | -0.06% | ||
More | ||||